Advanced Therapy Medicinal Products (ATMPs) embody innovative therapies that have created great hope for patients suffering from
previously untreatable diseases. Unfortunately, the pharaonic cost to produce and authorise ATMPs is a challenge for both patients
and public health care systems, ultimately reducing patients’ access to treatment. Over the last 11 years, only 15 ATMP marketing
authorisation applications received a positive draft opinion from the European Medicines Agency’s (EMA’s) Committee for Advanced
Therapies (CAT). Moreover, due to poor return on investment, several ATMPs have already been removed from the market. In addition
to the centralised procedure to obtain a marketing authorisation, the legislator foresees an alternative route for authorising ATMPs,
the so-called “ATMP Hospital Exemption”. However, such ATMPs must be produced on a limited scale, on a non-routine basis. As
a result, valuable ATMP therapies that have been used for years in hospitals may disappear. To avoid this, we propose, in this paper,
an additional possibility to regularise ATMPs: the “Magistral Preparation of ATMPs”. It is a feasible pathway, which was already
proposed for bacteriophage therapy, and which is particularly suitable for personalised therapies and considerably decreases the
cost of the final products. We also discuss the practical impact of the ATMP regulation for (for-profit) industries and for (non-profit)
hospitals. Two practical examples, the cultured human chondrocytes and the cultured human keratinocytes, are discussed.